Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.00EUR
2:07pm GMT
Change (% chg)

€-1.08 (-1.11%)
Prev Close
€97.08
Open
€97.18
Day's High
€97.44
Day's Low
€96.00
Volume
149,089
Avg. Vol
570,039
52-wk High
€100.20
52-wk Low
€74.54

Latest Key Developments (Source: Significant Developments)

Merck To Expand US Biopharmaceutical Research And Development Facility To Advance Innovative Clinical Pipeline
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - MERCK KGAA ::TO EXPAND US BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT FACILITY TO ADVANCE INNOVATIVE CLINICAL PIPELINE.EXPANSION OF RESEARCH AND DEVELOPMENT FOOTPRINT TO ACCELERATE SCIENCE AND INNOVATION IN ONCOLOGY, IMMUNO-ONCOLOGY AND IMMUNOLOGY GLOBALLY.MERCK KGAA, DARMSTADT, GERMANY INVESTING $70 MILLION IN U.S. RESEARCH & DEVELOPMENT HUB.  Full Article

Merck KGaA And GSK Agree On Collaboration In Immuno-Oncology
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Merck Kgaa ::DGAP-ADHOC: MERCK KGAA: MERCK AND GSK AGREE ON COLLABORATION IN IMMUNO-ONCOLOGY.COOPERATION RELATES TO M7824, A BIFUNCTIONAL FUSION PROTEIN DEVELOPED BY MERCK..WILL RECEIVE AN UPFRONT PAYMENT OF EUR300 MILLION AND IS ELIGIBLE FOR POTENTIAL DEVELOPMENT MILESTONE PAYMENTS OF UP TO EUR500 MILLION.TOTAL POTENTIAL DEAL VALUE IS UP TO EUR3.7 BILLION..  Full Article

Merck And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Merck KGaA ::MERCK AND PFIZER PROVIDE UPDATE ON AVELUMAB IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER.MERCK KGAA - SIGNALS WERE OBSERVED IN THE COMBINATION ARM RELATIVE TO PLD, AND FURTHER ANALYSES OF TRIAL ARE WARRANTED.MERCK - PHASE III JAVELIN OVARIAN 200 TRIAL DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS.MERCK KGAA - NO NEW SAFETY SIGNALS WERE OBSERVED FOR AVELUMAB ALONE OR IN COMBINATION.MERCK KGAA - SAFETY PROFILE FOR AVELUMAB IN TRIAL WAS CONSISTENT WITH OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM.MERCK - STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB & CHEMOTHERAPY.  Full Article

Merck KGaA Phase III Javelin Ovarian 200 Trial Did Not Reach Endpoints
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Merck Kgaa AND PFIZER ::PHASE III JAVELIN OVARIAN 200 TRIAL EVALUATING AVELUMAB* ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD), DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) OR PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-RESISTANT OR -REFRACTORY OVARIAN CANCER.DATA ARE CURRENTLY BEING ANALYZED, AND DETAILED RESULTS WILL BE SHARED WITH SCIENTIFIC COMMUNITY.RESEARCHER SAYS ALTHOUGH OS AND PFS DID NOT REACH STATISTICAL SIGNIFICANCE, STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB AND CHEMOTHERAPY WHICH WILL BE ANALYZED FURTHER.  Full Article

EMD Serono says Mavenclad Gets Positive CADTH Canadian Drug Committee Recommendation
Monday, 29 Oct 2018 

Oct 29 (Reuters) - EMD SERONO::MAVENCLAD (CLADRIBINE TABLETS) RECEIVES POSITIVE CADTH CANADIAN DRUG EXPERT COMMITTEE (CDEC) RECOMMENDATION.  Full Article

Merck: FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - MERCK KGAA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.NEW DRUG APPLICATION INCLUDES CLOSE TO 12,000 PATIENT YEARS OF DATA AND UP TO 10 YEARS OF SAFETY DATA IN SOME PATIENTS.  Full Article

FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - Merck KGaA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.EMD SERONO - RESUBMISSION OF NEW DRUG APPLICATION FOR CLADRIBINE TABLETS.EMD SERONO - RESUBMISSION FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MS ACCEPTED FOR FILING BY FDA.  Full Article

RBK EMD raises 7 bln won in private placement
Friday, 27 Jul 2018 

July 27 (Reuters) - RBK EMD Co Ltd <106080.KQ> ::Says it raised 7 billion won in private placement of 12,367,491 shares of the company.  Full Article

Merck KGaA Performance Materials CEO Says Doesn't Rule Out Smaller M&A
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Merck KGaA Performance Materials division CEO::SAYS BIG ACQUISITIONS WON'T HAPPEN UNTIL AFTER 2019, BUT CANNOT RULE OUT SMALLER ONES BEFORE THEN.SAYS DOESN'T SEE NEGATIVE IMPACT FROM U.S.-CHINA TRADE TARIFFS, MERCK DOESN'T HAVE MATERIAL STREAMS ACROSS AFFECTED REGIONS.  Full Article

Merck KGaA Receives Patent For CRISPR Technology In China
Monday, 23 Apr 2018 

April 23 (Reuters) - Merck KGaA ::MERCK RECEIVES PATENT FOR CRISPR TECHNOLOGY IN CHINA.  Full Article

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.